EUCTR2006-001860-22-IS
Active, not recruiting
Phase 1
CREATE. Cardiovascular Risk Evaluation and Attenuation of inflammation by early rosuvastatin TrEatment - CREATE
Karl Andersen0 sitesJuly 21, 2006
DrugsCrestor
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Karl Andersen
- Status
- Active, not recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with chest pain at rest or minimal physical activity of at least 20 minutes duration will be considered for inclusion in this study. To be eligible, patients have to be considered of low risk after being stable during a minimum period of 6 hours in the chest pain unit. They have to have at least two negative measurments of troponin T (less than 0\.1 mg/ml) drawn from periferal blood at 6 hour intervals. They may or may not have ischemic changes on EKG´s. After observation in the chest pain unit the patients that are considered not to have myocardial infarction or other need for hospital admission will be invited to participate in the study. These patients will be referred for a symptom limited exercise stress tesing on bicycle ergometry at a follow\-up visit 1\-2 weeks after their initial evaluation. The patients who have elevated hs\-CRP levels at the initial visit indicating an increased cardiovascular risk will be randomized to open\-label treatment with rosuvastatin 20 mg o.d. or no statin treatment. Patients with a previous history of ischemic heart disease, statin therapy, chronic or acute disease which can involve increased inflammatory activity will be excluded from the study. Blood samples will be collected for measurement of several markers of inflammation at baseline and 3 and 12 months after randomization. At 3 and 12 months clinical re\-evalutation will be made at a follow\-up visit, new blood samples collected for measurement of inflammatory markers and major adverse clinical events will be recorded.
- •To be randomized, patients have to fulfill all of the following criteria:
- •i.Patients considered at low risk of developing myocardial infarction after observation in the chest pain unit by at least two negative measurements of troponin T
- •ii.No sign of ongoing ischemia at rest
- •iii.Elevated hs\-CRP
- •iv.Informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
Exclusion Criteria
- •i.Elevated troponin T within the previous 30 days
- •ii.Previous history of atherosclerotic disease
- •iii.Need for hospitalisation due to myocardial instability or infarction
- •iv.Inability to perform excercise stress test
- •v.Bundle branch block or pacemaker rhythm precluding evalutation of ischemia
- •vi.Any condition, acute or chronic that is known to increase levels of inflammatory markers, (i.e. infection, arthritis, iflammatory bowel disease etc.)
- •vii.Ongoing statin treatment
- •viii.Patients who after examination turn out to have any other explanation for their chest pain than cardiac disorders
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
A clinical trial for Heart Disease Risk assessment and treatment of patients with high risk.Health Condition 1: I00-I99- Diseases of the circulatory systemCTRI/2019/04/018723Dr Saurabha Nayak
Not yet recruiting
Not Applicable
A Heart Health check for Maori and Pacific People in HospitalCardiovascular diseaseCardiovascular - Coronary heart diseaseStroke - IschaemicPublic Health - Health service researchACTRN12624000920594Christchurch Hospital Pharmacy Department200
Recruiting
Not Applicable
Validation and adoption of the cardiovascular risk algorithm in arriba for the German general practice setting.I20-I25I63Ischaemic heart diseasesCerebral infarctionDRKS00004633Gemeinnützige Gesellschaft für Patientenzentrierte Kommunikation mbH (GPZK)6,000
Not yet recruiting
Not Applicable
Assessment of cardio vascular risk by measurement of carotid intima-media thickness (cIMT) in adult type I Gaucher disease patients.Gaucher disease type Iglucocerebrosidase deficiency10027424NL-OMON29706Academisch Medisch Centrum140
Recruiting
Not Applicable
Study of effect of yoga in reducing cardiovascular disease risks in communityCTRI/2017/09/009770Jawaharlal Institute of Post graduate Medical Education and Research JIPMER1,000